Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Personalized weight loss: Gene-Targeted drug shows promise in obesity trial

NCT ID NCT03525002

First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 24 times

Summary

This study tested whether a drug called bromocriptine, which boosts dopamine in the brain, can help people with obesity lose weight. The key twist: the drug's effect may depend on a person's genetic makeup, specifically a gene called FTO. 120 participants took either bromocriptine or a placebo for 18 weeks, and researchers tracked weight changes and eating habits to see if the drug works better for certain genetic profiles.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • University Hospital Cologne

    Cologne, Germany

  • University Hospital Luebeck

    Lübeck, Germany

  • University of Tuebingen, Department of Internal Medicine IV

    Tübingen, 72076, Germany

Conditions

Explore the condition pages connected to this study.